Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895211 | 0.78 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL29345090 | 0.74 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3CYP1A2 | |
| SCHEMBL8007592 | 0.72 | NR1H2 (0.40) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL9895976 | 0.69 | CHRM2 (0.34) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL20990302 | 0.69 | NR1H2 (0.39) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL17842640 | 0.68 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL19639853 | 0.68 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL17848777 | 0.68 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL29558378 | 0.68 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3GPR119 | |
| SCHEMBL7900483 | 0.68 | NR1H2 (0.41) | NR1H2CHRM2CHRM1CHRM3CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149711-A1 | PIPERIDINE DERIVATIVES USED AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, OXTR | NR1H2 344/4885CHRM2 778/4885CHRM1 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.